GlassScriptPhysician profile
Kristen E Wissbaum
NPI 1356972483
$3,282.23
in general payments reported to CMS, 2019-2025
42 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $778 · 2022: $200 · 2023: $1,106 · 2024: $895 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,187 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,186.65 |
| Education | $117.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $254.04 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Incyte Corporation | $232.67 | 2021-2024 | Pemazyre, Monjuvi, Jakafi |
| Daiichi Sankyo INC. | $196.49 | 2023-2025 | Enhertu, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $193.18 | 2022-2024 | Iclusig, Ninlaro, Alunbrig |
| E.R. Squibb & Sons, L.L.C. | $192.01 | 2021-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $188.03 | 2021-2025 | Calquence |
| Eisai INC. | $174.29 | 2021-2025 | |
| Lilly USA, LLC | $162.06 | 2023 | Jaypirca, Retevmo, Verzenio |
| Pharmacosmos Therapeutics INC. | $147.63 | 2023-2024 | Monoferric |
| Foundation Medicine, INC. | $146.87 | 2023 | Foundationone Cdx, Foundationone Liquid Cdx |
| Merck Sharp & Dohme LLC | $135.40 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Biotech, INC. | $103.24 | 2023-2025 | Tecvayli, Darzalex, Talvey |
| Heron Therapeutics, INC. | $91.08 | 2021 | |
| Novartis Pharmaceuticals Corporation | $77.83 | 2023-2024 | |
| Seagen INC. | $73.69 | 2023 | Tukysa, Adcetris |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Wissbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.